KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Net Income (2017 - 2025)

Historic Net Income for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$15.4 million.

  • Aquestive Therapeutics' Net Income fell 3420.8% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.0 million, marking a year-over-year decrease of 9600.2%. This contributed to the annual value of -$44.1 million for FY2024, which is 46082.59% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Net Income is -$15.4 million, which was down 3420.8% from -$13.5 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Net Income peaked at $8.1 million during Q1 2023, and registered a low of -$28.9 million during Q4 2021.
  • In the last 5 years, Aquestive Therapeutics' Net Income had a median value of -$12.8 million in 2024 and averaged -$12.0 million.
  • Its Net Income has fluctuated over the past 5 years, first surged by 16102.87% in 2023, then crashed by 46555.28% in 2024.
  • Aquestive Therapeutics' Net Income (Quarter) stood at -$28.9 million in 2021, then surged by 57.33% to -$12.4 million in 2022, then soared by 34.33% to -$8.1 million in 2023, then crashed by 110.27% to -$17.1 million in 2024, then increased by 9.43% to -$15.4 million in 2025.
  • Its last three reported values are -$15.4 million in Q3 2025, -$13.5 million for Q2 2025, and -$22.9 million during Q1 2025.